“The African Centers for Disease Control and Prevention (Africa CDC) is in talks with Bavarian Nordic to facilitate technology transfer for African manufacturers,” said Dr. Jean Kaseya, the Director General of the Africa CDC, who addressed the continent on the Mpox outbreak and other health emergencies in Africa. Dr.
Kaseya called for the importance of collaboration between Bavarian Nordic and the African CDC to ensure vaccine accessibility. “We have a clear plan to have these 10 million doses in Africa by the end of 2025,” he said. Furthermore, he expressed gratitude for the European Union’s assistance procuring 215,000 doses through its emergency humanitarian initiative.
Africa had experienced a 160% increase in Mpox cases compared to the same period in 2023 “We are working with all African member states to see how we can strengthen the supply and we can also strengthen the communication component to ensure a smooth introduction of this vaccine in Africa,” said Dr. Kaseya. “The most important one for me as Director-General of Africa CDC is to say every day, we need local manufacturing.
I want to recognise and thank Bavaria Nordic for agreeing to do the tech transfer in Africa so that Africa can manufacture the vaccine at a lower price and without compromising on the quality.” The Danish biotechnology company, Bavarian Nordic, played a crucial role in controlling the outbreak by rapidly developing the Jynneos vaccine, also known as Imvanex, during the initi.